[Balancing drug regulation and health democracy: The role of patient and healthcare professional advisors at the ANSM].

Concilier régulation du médicament et démocratie sanitaire : rôle des conseillers patient ou professionnel de santé à l’ANSM.
Conseillers Drug evaluation Démocratie sanitaire Health democracy Health products regulation, Advisors Healthcare professional Patient advocacy Patient partenaire Professionnels de santé Régulation des produits de santé Évaluation des médicaments

Journal

Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544

Informations de publication

Date de publication:
22 Jun 2024
Historique:
received: 26 03 2024
revised: 27 05 2024
accepted: 17 06 2024
medline: 7 7 2024
pubmed: 7 7 2024
entrez: 6 7 2024
Statut: aheadofprint

Résumé

The French National Agency for Health Products (ANSM) is a regulatory and public health agency. Its regulatory, health policing and public health protection activities require a perfect fit with the field and the various people involved in the use of health products. Since 2019, the ANSM has adapted its organisation, procedures and processes to encourage and improve interaction with its stakeholders, as part of its policy of openness towards civil society. To accompany this ambitious change and to support its staff, the Agency has recruited advisors corresponding to the main users of health products: prescribers (doctor's hospital and outpatient), pharmacists and patients. Working as a group or individually, they provide a "lived" user perspective on health products at each stage of the evaluation process. They may be involved in the assessment of dossiers, signals or applications received by the Agency, in the internal validation of reports or in discussions with stakeholders. They are particularly involved when the analysis requires expertise that goes beyond the technical, scientific or regulatory aspects. They may also work with ANSM staff to explain certain processes and difficulties in the field. Advisors help to ensure that regulatory and/or scientific expertise is clear and consistent with user experience. In addition to their scientific and therapeutic aspects, medicines are also economic, social and political issues. Their regulation is therefore particularly affected by the need for health democracy. This requires the active participation of health professionals, patients and, more broadly, civil society in the decision-making process. Civil society is a space occupied by a wide range of actors who exert pressure from different ideological positions to influence the regulation of health products. In this context, taking into account a plurality of viewpoints in the regulation of health products is necessary and complex, but its operation can be facilitated by the collective efforts of the actors and the adaptation of organisations, such as the integration of advisors.

Identifiants

pubmed: 38971714
pii: S0040-5957(24)00070-2
doi: 10.1016/j.therap.2024.06.002
pii:
doi:

Types de publication

English Abstract Journal Article

Langues

fre

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Agence Nationale de Sécurité du Médicament. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Patrick Maison (P)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France; EA 7379, faculté de santé, université Paris-Est Créteil, CHI de Créteil, 94000 Créteil, France. Electronic address: Patrick.MAISON@ansm.sante.fr.

Trystan Bacon (T)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France; Collège universitaire de médecine générale, université Claude-Bernard Lyon 1, 69000 Lyon, France.

Pascale Daynes (P)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France; Union francophone des patients partenaires, faculté de médecine, centre hospitalier universitaire Grenoble-Alpes, 38700 La Tronche, France.

Christophe Decoene (C)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France; Pôle anesthésie-réanimation, centre hospitalier universitaire de Lille, 59000 Lille, France.

Roseline Mazet (R)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France; Centre hospitalier universitaire de Grenoble-Alpes, 38000 Grenoble, France.

Thierry Vial (T)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France; Service hospitalo-universitaire de pharmacotoxicologie, hospices civils de Lyon, 69000 Lyon, France.

Stéphane Vignot (S)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France; EA7509 IRMAIC, université de Reims Champagne-Ardenne, 51100 Reims, France; Département d'oncologie médicale, institut Godinot, 51100 Reims, France.

Laetitia Belgodère (L)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France.

Wahiba Oualikene-Gonin (W)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France.

Christelle Ratignier-Carbonneil (C)

Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France.

Classifications MeSH